Advertisement
Advertisement

ESPR

ESPR logo

Esperion Therapeutics, Inc.

3.15
USD
Sponsored
0.00
+0.16%
Jun 25, 09:30 UTC -4
Open

ESPR Earnings Reports

Positive Surprise Ratio

ESPR beat 23 of 42 last estimates.

55%

Next Report

Date of Next Report
Aug 03, 2026
Estimate for Q2 26 (Revenue/ EPS)
$94.28M
/
$0.00
Implied change from Q1 26 (Revenue/ EPS)
+17.69%
/
-100.00%
Implied change from Q2 25 (Revenue/ EPS)
+14.43%
/
-100.00%

Esperion Therapeutics, Inc. earnings per share and revenue

On May 08, 2026, ESPR reported earnings of -0.10 USD per share (EPS) for Q1 26, missing the estimate of -0.03 USD, resulting in a -192.40% surprise. Revenue reached 80.10 million, compared to an expected 86.21 million, with a -7.09% difference. The market reacted with a -0.32% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 6 analysts forecast an EPS of 0.00 USD, with revenue projected to reach 94.28 million USD, implying an decrease of -100.00% EPS, and increase of 17.69% in Revenue from the last quarter.
FAQ
For Q1 2026, Esperion Therapeutics, Inc. reported EPS of -$0.10, missing estimates by -192.4%, and revenue of $80.10M, -7.09% below expectations.
The stock price moved down -0.32%, changed from $3.15 before the earnings release to $3.14 the day after.
The next earning report is scheduled for Aug 03, 2026.
Based on 6 analysts, Esperion Therapeutics, Inc. is expected to report EPS of -- and revenue of $94.28M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement